Call Now

Human FABP5 / E-FABP Protein

E-FABP,EFABP,KFABP,PA-FABP,PAFABP

Catalog Number P12581-HNAE
Organism Species Human
Host E. coli
Synonyms E-FABP,EFABP,KFABP,PA-FABP,PAFABP
Molecular Weight The recombinant human FABP5 consisting of 135 amino acids and has a calculated molecular mass of 15.2 kDa as estimated in SDS-PAGE under reducing conditions.
predicted N Met 1
SDS-PAGE
Purity > 92 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the human FABP5 (Q01469) (Met 1-Glu 135) was expressed and purified.
Bio-activity
Research Area Developmental Biology |Metabolism |Pathways and Processes |Metabolic signaling pathways |Lipid and lipoprotein metabolism |Fatty acids |
Formulation Lyophilized from sterile 50mM Tris, pH 8.0
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Fatty acid-binding protein, also known as Epidermal-type fatty acid-binding protein, Fatty acid-binding protein 5, Psoriasis-associated fatty acid-binding protein homolog, E-FABP and FABP5, is a cytoplasm protein which Belongs to the calycin superfamily and Fatty-acid binding protein (FABP) family. Fatty acid-binding proteins ( FABPs ) are postulated to serve as lipid shuttles that solubilize hydrophobic fatty acids and deliver them to appropriate intracellular sites. E-FABP / FABP5 is predominantly expressed in keratinocytes and is overexpressed in the actively proliferating tissue characteristic of psoriasis and wound healing. E-FABP / FABP5 exhibits an important role in binding free fatty acids, as well as regulating lipid metabolism and transport. E-FABP / FABP5 has high specificity for fatty acids. It has highest affinity for C18 chain length. Decreasing the chain length or introducing double bonds reduces the affinity of FABP5. E-FABP / FABP5 may be involved in keratinocyte differentiation.
Reference
  • Hohoff C., et al., 1999, Biochemistry 38:12229-39
  • Gutierrez-Gonzalez L.H., et al., 2002, Biochem. J. 364:725-37.
  • Ogawa,E. et al., 2011, J Invest Dermatol. 131 (3):604-12.
  • Ma,X. et al., 2010, Mol Biol Rep. 37 (8):4003-11.